Satellite Symposia

To provide additional educational opportunities at AMCP Nexus 2019, AMCP also allows non-commercial, grant-supported satellite symposia. These learning activities are developed by medical education organizations and are an important part of the conference. Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit. All satellite symposia will be held at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.

Tuesday, October 29, 2019| 11:00 am – 12:30 pm

 

SS1:  Continuous Glucose Monitoring and the Opportunities for Optimal Diabetes Care and Cost Management

Jointly provided by Impact Education, LLC and Medical Education Resources, Inc.
Supported by an independent educational grant from DexCom.
Continuing education credit available for pharmacists and physicians.

Program Description

The vast majority of plan members with diabetes have an A1C above ADA targets, putting them at risk for other costly comorbidities. To effectively address these clinical challenges and elicit improvements across 29 indices of glycemic control and glycemic variability, continuous glucose monitoring (CGM) has been endorsed by various professional endocrinology-centered organizations. In 2017, the Centers for Medicare and Medicaid Services (CMS) Medicare made a milestone ruling, establishing benefit coverage for “therapeutic” CGM—a designation applying to those CGM systems approved for use in making treatment decisions without a fingerstick (“non-adjunctive use”). This program will elucidate the burden of diabetes and describe multifaceted clinical and administrative strategies across the medical and pharmacy benefits to promote quality care and manage costs while improving outcomes for affected plan members.

Learn about:
Cutting edge and fast-growing interventions such as real-time continuous glucose monitoring and validating the value of new technologies in comprehensive disease management programming.

Program Manager
Steven Casebeer, MBA
Impact Education, LLC
info@impactedu.net
215-619-8812 | Ext. 102

No Fee Registration: www.managedcarecgm.com/nexus

SS2:  Rethinking Treatment in Rheumatoid Arthritis: Novel Approaches for Better Outcomes

Provided by PRIME Education, LLC
Supported by an independent educational grant from Gilead Sciences, Inc.
Continuing education credit available for pharmacists, physicians and nurses.

Program Description

In this informative session, an interprofessional panel of rheumatoid arthritis (RA) and managed care experts will review the latest evidence coming from EULAR and other major rheumatology meetings. The panel discussion will focus on strategies to align managed care decision-making with current evidence in RA management.

Reasons to Attend:
• Updates from EULAR and other major conferences
• The latest on therapy selection and patient-centered care in the modern era
• Case-based discussion on managed care strategies and decision-making for complex patients
• Expert Q&A: Answers to your most pressing questions

Program Manager
Tammy Gonzalez
PRIME Education, LLC
t.gonzalez@primeinc.org
954-718-6055

No Fee Registration: Click Here

Tuesday, October 29, 2019 | 6:00 pm – 8:00 pm

 

SS03: The Promise of Gene Therapy: Access and Coverage for Innovative, High-Cost Treatments

Jointly provided by the National Hemophilia Foundation, Medical Education Resources, Inc. and Impact Education, LLC.
Supported by independent educational grants from BioMarin Pharmaceutical Inc. and uniQure.
Continuing education credit available for pharmacists and physicians.

Program Description

The treatment of hemophilia continues to advance and emerging products have demonstrated the potential for improved management, increased patient adherence, and enhanced outcomes. The most recent of these advancements, gene therapy, has demonstrated tremendous promise in terms of offering at least temporarily curative potential.

While the cost of gene therapy for hemophilia is anticipated to be sizably greater than that of currently prescribed agents, many opinion leaders anticipate it to be a “once in a lifetime treatment.” As a result, the anticipated high cost of gene therapy will likely be offset by the avoidance of continued factor replacement therapy and other components of health care resource utilization. Still, the prospect of a significantly larger, albeit potentially one-time drug acquisition cost presents a challenge for payers and the standard models used to cover and pay for prescription drugs. Therefore, innovators, health insurers, and policymakers have been discussing alternative payment arrangements, such as a large upfront payment followed by installments (akin to a mortgage) and outcomes-based contracting and payments. The latter approach has already been applied in other disease states with high-cost therapies for rare diseases. A key element in these discussions is the consideration of health insurance subscriber retention.

Program Manager
Steven Casebeer, MBA
Impact Education, LLC
info@impactedu.net
215-619-8812 | Ext. 102

No Fee Registration: www.impactedu.net/genetherapynexus2019

SS04: Improve Management of Patients at Risk of ASCVD Events:  Implications of the NEW Cholesterol Guidelines and CV Outcomes Trials

Jointly provided by Postgraduate Institute for Medicine (PIM) and The Omnia-Prova Education Collaborative (TOPEC).
Supported by an independent educational grant from Amarin Pharma, Inc.
Continuing education credit available for pharmacists and physicians.

Program Description

This live activity will feature nationally recognized pharmacy leaders in managing ASCVD risk, sharing the latest evidence and clinical practice pearls to managed care pharmacists. Short didactic presentations, incorporating ARS question and answer format will engage the participants. The program will begin with an introduction to the new 2018 Blood Cholesterol guides and examine what is new and appreciate the management algorithm for primary and secondary prevention. The next presentation will provide detailed information on the recent CVD outcomes trials, especially those that have proven benefits and provide new options for ASCVD management. The final presentation will provide a perspective for the managed care pharmacist that will incorporate the guidelines, recent data, and managed care implications to give attendees an educated framework for their decision making in this area. The session will end with the faculty/participant panel discussion of relevant clinical practice issues/challenges.

Program Manager
Jessica McGrory
Medtelligence, Inc.
jmcgrory@omnia-prova.com
267-464-0951

No Fee Registration: Click Here

Wednesday, October 30, 2019 | 6:00 am – 8:00 am

 

SS05: Navigating Cannabidiol Use in Seizure Disorders: A Roadmap for Managed Care and Specialty Pharmacists

Provided by Postgraduate Healthcare Education, LLC.
Supported by an independent educational grant from Greenwich Biosciences.
Continuing education credit available for pharmacists.

Program Description

Treatment of seizure disorders in children is often a difficult, trial-and-error process with a high rate of resistance, poor disease control with breakthrough seizures, and intolerable adverse effects related to monotherapy or combination therapies. Some seizure disorders have not responded well to standard antiepileptic drug regimens. Examples are Dravet syndrome, a catastrophic early-onset encephalopathic epilepsy with, up until just recently, no approved antiepileptic treatments in the US; and, Lennox-Gastaut, a syndrome associated with hard-to-control drop seizures typically unresponsive to antiepileptic therapies. Parents of children with these disorders usually must go through a frustrating range of approaches including medication, lifestyle, and diet changes in an effort to control the disease.

Cannabidiol (CBD), a key active ingredient in Cannabis, is a substance being studied extensively for its pharmacologic properties in many disease states, including seizure disorders. The recent FDA approval of a purified oral CBD solution- indicated for the two difficult-to-treat seizure types, Lennox Gastaut and Dravet syndromes- marked a breakthrough on many levels. This symposium will provide the most current information on the novel use of CBD in severe seizure disorders including mechanism of action, legal and regulatory issues, differences among Cannabis derived substances, and implications to the practice of managed care and specialty pharmacy.

Program Manager
Susan R. Grady, MSN, RN-BC
Postgraduate Healthcare Education LLC (PowerPak C.E.)
sgrady@postgradhealthed.com
609- 234-3323

No Fee Registration: Click Here

Wednesday, October 30, 2019 | 6:30 pm – 8:30 pm

 

SS06: Implications of New ACC/AHA Cholesterol Guidelines on Managed Care Decision-Making for Patients with ASCVD

Provided by PRIME Education, LLC
Supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.
Continuing education credit available for pharmacists, physicians and nurses.

Program Description

Join experts Dana McCormick, RPh, Kim Caldwell, RPh, Pam Taub, MD, and Harold Bays, MD, as they discuss all-new data from a 2019 survey of cardiologists and managed care professionals on the state of cholesterol management across the US. Examining the landscape through the lens of recent landmark changes in cholesterol management, they will explore the latest data and applications for managed care decision-making to optimize management of high-risk cholesterol patients.

Don't miss these preeminent experts as they discuss:

• NEW survey data on the state of cholesterol management presented for the first time at this live symposium!
• Insights from across the US: key findings addressing quality of care gaps
• Implications of new ACC/AHA cholesterol guidelines on managed care decision-making for patients with atherosclerotic cardiovascular disease

This can't-miss live session is designed to provide extensive face-to-face interactive learning, peer discussion, and dedicated time for Q&A.

Program Manager
Tammy Gonzalez
PRIME Education, LLC
t.gonzalez@primeinc.org
954-718-6055

No Fee Registration: Click Here

SS07: The Right Drugs at the Right Time: The Cost-Savings Case for Tying PAH Formulary Protocols to Best Available Clinical Evidence

Provided by Academy for Continued Healthcare Learning and Purdue University, College of Pharmacy.
Supported by independent educational grants from Actelion Pharmaceuticals US, Inc., and Bayer HealthCare Pharmaceuticals.
Continuing education credit available for pharmacists.

Program Description

Therapeutic selection and management in PAH are intertwined with differential diagnostics, disease classification, and risk stratification. If the incorrect disease classification/risk stratification is made at the incorrect time, inappropriate therapy is often offered, resulting in poor clinical outcomes. Managed care pharmacists must be prepared to update formularies and related dispensing/management protocols to improve outcomes and manage the high costs associated with unnecessary hospitalizations. Our expert faculty, comprised of a managed care pharmacist and pulmonologist specializing in PAH, will review recent guideline recommendations and strategies for selecting initial combination therapy, as well as how to make this a financial reality based on managed care pharmacy protocols.

Program Manager
Laurie Novoryta
Academy for Continued Healthcare Learning
Lnovoryta@achlcme.org
773-714-0705, ext. 205

No Fee Registration: Click Here

Thursday, October 31, 2019 | 6:00 am – 7:45 am

 

SS08: Employing Immuno-Oncology Biomarkers to Guide Treatment Decision Making: Managed Care and Specialty Pharmacist Perspectives

Provided by Postgraduate Healthcare Education, LLC.
Supported by independent educational grants from Bristol-Myers Squibb and Merck & Company.
Continuing education credit available for pharmacists.

Program Description

While genomics has led the field of personalized cancer medicine over the past several decades by connecting patient-specific DNA mutations with kinase-targeted drugs, the recent discovery that tumors evade immune surveillance has created unique challenges to personalize cancer immunotherapy. Novel clinical-grade biomarkers can guide the choice of these agents to obtain the maximal likelihood of patient benefit. The identification of immunotherapy biomarkers enables the identification of patients most likely to derive a therapeutic response to immune checkpoint inhibitors. Being able to predict who will achieve maximum benefit from therapy will not only lead to better outcomes but should positively impact healthcare expenditures as well. This symposium will provide the most up-to-date science on contemporary uses of biomarkers in immuno-oncology treatment decision making and how pharmacists can impact many aspects of both drug therapy and formulary management thus leading to improved access to care and outcomes.

Program Manager
Susan R. Grady, MSN, RN-BC
Postgraduate Healthcare Education LLC (PowerPak C.E.)
sgrady@postgradhealthed.com
609-234-3323

No Fee Registration: Click Here

SS09: An American Journal of Managed Care Symposium: Living with Psoriatic Disease

Provided by Pharmacy Times Continuing Education.
Supported by independent educational grant from Lilly.
Continuing education credit available for pharmacists.

Program Description

A greater understanding of the immunologic, genetic, and autoimmune characteristics of psoriasis (PsO) has improved substantially in the past decade. PsO is more than a dermatologic condition and patients with severe disease have a higher mortality rate with a 50% greater risk of premature death, most likely due to the presence of comorbidities. Managed care professionals, pharmacy benefit managers, and specialty pharmacists should be familiar with the economic burden associated with PsO and psoriatic arthritis (PsA), the associated comorbidities, the importance of early intervention, and the availability of newer biologics and emerging agents in the treatment and management of these diseases. This session will highlight important ways to consider the effectiveness and cost-efficacy data along with patients’ preferences and disease severity in ascertaining how to optimize care for patients with PsO and PsA.

Program Manager:
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
609-325-4842

No Fee Registration: Click Here

Thursday, October 31, 2019 | 6:00 pm – 8:00 pm

 

SS10: Conundrums and Opportunities with Anticoagulation in CAD, PAD, and VTE

Provided by Medtelligence, Inc. and The Annenberg Center for Health Sciences at Eisenhower.
Supported by an independent educational grant from Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC.
Continuing education credit available for pharmacists.

Program Description:
This live activity will feature nationally recognized leaders in managing anticoagulation in patients with coronary artery disease (CAD), peripheral vascular disease (PVD) and venous thromboembolism (VTE) sharing the latest evidence and clinical practice pearls to managed care pharmacists. Short didactic presentations, incorporating ARS question and answer format will engage the participants.

The program will begin with a review of important clinical trials, including COMPASS and the rationale for adding anticoagulant therapy. The faculty will also examine new data on VTE prevention including discussion of EINSTEIN and RECOVER trials and drug dosing and safety considerations. Finally, discussion on the Managed Care Pharmacists role in chronic management of polyvascular disease will feature guidelines, economics and a pharmacy checklist on anticoagualation that will incorporate the guidelines, recent data, and managed care implications to give attendees an educated framework for their decision making in this area.
The session will end with the faculty/participant panel discussion of relevant clinical practice issues/challenges.

Program Manager:
Jessica McGrory
Medtelligence, Inc.
jmcgrory@omnia-prova.com
267-464-0951

No Fee Registration: Click Here